Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

470

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Cancer

Interventions

DRUG: Iza-bren
DRUG: Cisplatin
DRUG: Gemcitabine
DRUG: Carboplatin

Sponsor

Bristol-Myers Squibb